PT-141 10MG

PT-141 10MG

$62.00

PT-141 is a synthetic derivative of alpha-melanocyte-stimulating hormone that targets melanocortin receptors to enhance sexual arousal. It has been studied for treating sexual desire disorders.

53 in stock (can be backordered)

Quantity Discount / Amount Price
5 5% $58.90
10 10% $55.80
Summary
PT-141 10MG$62.00
$62.00

Product Usage: This product is designated as a "Novelty Peptide" and is intended solely for specialized applications in controlled settings. It is not intended for any specific biological, therapeutic, or diagnostic use. All information provided on this website is for informational and educational purposes only and should not be construed as guidance for any particular application or usage.

download

PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It functions as a melanocortin receptor agonist, primarily targeting the melanocortin 4 receptor (MC4R). PT-141 was initially developed as a potential treatment for sexual dysfunction in both men and women. Unlike traditional erectile dysfunction medications that affect the vascular system, PT-141 works through the nervous system, potentially increasing both sexual desire and physical arousal.

Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Molecular Formula: C50H68N14O10

Molecular Weight: 1025.2 g/mol

CAS Number: 189691-06-3

  1. Sexual Dysfunction Treatment: Clinical trials have demonstrated PT-141's efficacy in treating both male erectile dysfunction and female sexual arousal disorder. In men with erectile dysfunction, PT-141 significantly increased the duration of erections compared to placebo.
  2. Rapid Onset of Action: Studies have shown that PT-141 can induce an erectile response in approximately 30 minutes, with effects lasting up to 12 hours.
  3. Central Nervous System Activation: PT-141 has been observed to activate neurons in the hypothalamus, as evidenced by increased c-Fos immunoreactivity in animal studies.
  4. Synergistic Effects: When combined with PDE5 inhibitors like sildenafil, PT-141 showed enhanced efficacy in treating erectile dysfunction compared to either drug alone.
  5. Safety Profile: Clinical trials have generally found PT-141 to be well-tolerated, with most side effects being mild to moderate. The most common adverse events reported were flushing, nausea, and headaches.

  1. Long-term Safety Studies: Extended research is needed to evaluate the long-term effects and safety profile of PT-141, particularly for chronic use.
  2. Mechanism of Action: Further investigation into the precise neurological pathways through which PT-141 exerts its effects could lead to improved understanding and potentially new therapeutic applications.
  3. Combination Therapies: Exploring potential synergistic effects of PT-141 with other treatments for sexual dysfunction could open new avenues for more effective therapies.
  4. Expanded Clinical Applications: Research into PT-141's potential benefits for other conditions related to sexual function or desire disorders is warranted.
  5. Optimal Dosing Regimens: Studies to determine the most effective dosing strategies for different patient populations and conditions could enhance the therapeutic potential of PT-141.

  1. Diamond, L.E., et al. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research, 16(1), 51-59. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/14963471/
  2. Rosen, R.C., et al. (2004). Effects of PT-141, a melanocortin analog, on sexual desire and physiological arousal in men and women. Menopause, 11(6 Pt 2), 782-791. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/15543025/
  3. King, S.H., et al. (2007). Melanocortin receptors, melanotropic peptides and penile erection. Current Topics in Medicinal Chemistry, 7(11), 1098-1106. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694735/
  4. Safarinejad, M.R. (2008). Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. Journal of Sexual Medicine, 5(4), 887-897. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/18179458/
  5. Molinoff, P.B., et al. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96-102. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/12851303/
PT-141 (Bremelanotide) represents a promising avenue for the treatment of sexual dysfunction in both men and women. As with all peptide therapies, it is important to use PT-141 under medical supervision, and its potential benefits and risks require ongoing evaluation through long-term clinical use and further research.